Ramanath Dukkipati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ramanath Dukkipati has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Kamyar Kalantar-Zadeh
Division of Nephrology and Hypertension and Transplantation, Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, California
4 shared publications Rajiv Dhamija
Rancho Los Amigos National Rehabilitation Center, Downey, California
3 shared publicationsAnuja Shah
Harbor-UCLA Medical Center, Torrance, California, USA
2 shared publicationsChristian de Virgilio
Harbor-UCLA Medical Center, Torrance, California, USA
2 shared publicationsGautam Tammewar
Los Angeles Biomedical Research Institute at Harbor‐UCLA Medical Center and the David Geffen School of Medicine at UCLA, Torrance and Los Angeles, California
2 shared publicationsJoel D. Kopple
Los Angeles Biomedical Research Institute at Harbor‐UCLA Medical Center, Los Angeles, California
2 shared publications
Latest Publications
- Open Access
- 16 April 2022
- Published by Hindawi Limited in Case Reports in Vascular Medicine
- Vol. 2022, 1-6
Iatrogenic Fistula in Hemodialysis Patients: An Alternative Approach to Thrombectomy of Arteriovenous Graft (AVG) Thrombosis
Arterial venous (AV) fistula is the first choice of vascular access to perform hemodialysis in the vast majority of suitable patients followed by arteriovenous grafts (AVG). An iatrogenic fistula can occur when a second vein adjacent to the graft is punctured and the needle traverses the vein. In normal circumstances, this has no clinical repercussions and does not need correction, and in prior reports, it has helped to maintain the patency of partially occluded grafts but rarely can lead to thrombosis of the graft due to reduced flow and pressure in the graft lumen. We report here what we believe is a unique approach to perform thrombectomy of an occluded graft in a 71-year-old patient on hemodialysis to avoid placement of tunneled hemodialysis catheters and complications associated with catheters. When the outflow of basilic vein in this patient was thrombosed and could not be traversed, we successfully used an iatrogenic fistula as main outflow vein for the graft and created an alternative vein for drainage thus avoiding placement of a tunneled catheter for hemodialysis.
- 16 April 2022
- Published by Hindawi Limited in Case Reports in Vascular Medicine
- Vol. 2022, 1-6
Open AccessIatrogenic Fistula in Hemodialysis Patients: An Alternative Approach to Thrombectomy of Arteriovenous Graft (AVG) Thrombosis
Arterial venous (AV) fistula is the first choice of vascular access to perform hemodialysis in the vast majority of suitable patients followed by arteriovenous grafts (AVG). An iatrogenic fistula can occur when a second vein adjacent to the graft is punctured and the needle traverses the vein. In normal circumstances, this has no clinical repercussions and does not need correction, and in prior reports, it has helped to maintain the patency of partially occluded grafts but rarely can lead to thrombosis of the graft due to reduced flow and pressure in the graft lumen. We report here what we believe is a unique approach to perform thrombectomy of an occluded graft in a 71-year-old patient on hemodialysis to avoid placement of tunneled hemodialysis catheters and complications associated with catheters. When the outflow of basilic vein in this patient was thrombosed and could not be traversed, we successfully used an iatrogenic fistula as main outflow vein for the graft and created an alternative vein for drainage thus avoiding placement of a tunneled catheter for hemodialysis.
- Open Access
- 9 September 2021
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 11 (3) , 275-280
Median Nerve and Ulnar Nerve Entrapment with Cubital Tunnel Syndrome in a Hemodialysis Patient Following Creation of an Arteriovenous Fistula
Neurological and vascular complications associated with creation of arteriovenous access need to be recognized promptly to deliver appropriate interventions for relief of symptoms and avoid loss of function of the involved extremity. We present here a 55-year-old female with end-stage renal disease on hemodialysis secondary to diabetic nephropathy who had a surgical creation of first stage of the brachial artery-basilic vein fistula in the left arm. She subsequently developed pain and weakness of the left arm which was diagnosed as median and ulnar nerve entrapment. She was treated with surgical nerve release and neurolysis and her symptoms improved.
- 9 September 2021
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 11 (3) , 275-280
Open AccessMedian Nerve and Ulnar Nerve Entrapment with Cubital Tunnel Syndrome in a Hemodialysis Patient Following Creation of an Arteriovenous Fistula
Neurological and vascular complications associated with creation of arteriovenous access need to be recognized promptly to deliver appropriate interventions for relief of symptoms and avoid loss of function of the involved extremity. We present here a 55-year-old female with end-stage renal disease on hemodialysis secondary to diabetic nephropathy who had a surgical creation of first stage of the brachial artery-basilic vein fistula in the left arm. She subsequently developed pain and weakness of the left arm which was diagnosed as median and ulnar nerve entrapment. She was treated with surgical nerve release and neurolysis and her symptoms improved.
- Open Access
- 29 May 2021
- Published by Wiley in Case Reports in Nephrology
- Vol. 2021, 1-4
Bartonella-Associated Endocarditis with Severe Active Crescentic Glomerulonephritis and Acute Renal Failure
We report a case of severe acute kidney failure due to crescentic glomerulonephritis who presented initially with culture-negative endocarditis with vegetations on the aortic valve. Anti-nuclear and anti-phospholipid antibodies were positive with initially negative anti-neutrophil cytoplasmic antibodies (ANCAs). Kidney biopsy revealed severe acute crescentic glomerulonephritis with mesangial immune complex deposition. PR3-ANCA subsequently become positive, and the patient developed worsening kidney failure requiring hemodialysis. This case illustrates that Bartonella can present as culture-negative endocarditis with severe crescentic glomerulonephritis with positive PR-3 ANCAs and can mimic ANCA-associated crescentic glomerulonephritis.
- 29 May 2021
- Published by Wiley in Case Reports in Nephrology
- Vol. 2021, 1-4
Open AccessBartonella-Associated Endocarditis with Severe Active Crescentic Glomerulonephritis and Acute Renal Failure
We report a case of severe acute kidney failure due to crescentic glomerulonephritis who presented initially with culture-negative endocarditis with vegetations on the aortic valve. Anti-nuclear and anti-phospholipid antibodies were positive with initially negative anti-neutrophil cytoplasmic antibodies (ANCAs). Kidney biopsy revealed severe acute crescentic glomerulonephritis with mesangial immune complex deposition. PR3-ANCA subsequently become positive, and the patient developed worsening kidney failure requiring hemodialysis. This case illustrates that Bartonella can present as culture-negative endocarditis with severe crescentic glomerulonephritis with positive PR-3 ANCAs and can mimic ANCA-associated crescentic glomerulonephritis.
- Open Access
- 9 October 2014
- Published by Wiley in Seminars in Dialysis
- Vol. 28 (1) , E7-E10
Outcomes of Cephalic Arch Stenosis With and Without Stent Placement after Percutaneous Balloon Angioplasty in Hemodialysis Patients
Cephalic arch stenosis is a common complication in maintenance hemodialysis (MHD) patients with brachial artery‐cephalic vein fistulas and frequently leads to loss of the functioning brachial artery‐cephalic vein fistula. There is paucity of conclusive data to guide appropriate management. We examined the risk of recurrence of cephalic arch stenosis after angioplasty compared to angioplasty after stent placement determined by angiography of the involved upper extremity over time in a contemporary cohort of MHD patients treated in two interventional nephrology practices from March 2008 through May 2011. We retrospectively identified 45 MHD patients with evidence of cephalic arch stenosis (age 60 ± 30 years, 45% men) on elective angiograms. The median number of days until another angioplasty was required decreased, starting with a median of 91.5 days after the first, 70.5 days after the second, 85 days after the third, and 56 days after the fourth. Angioplasty is associated with a faster rate of recurrence of cephalic arch stenosis. The placement of intravascular stent seems to prolong the patency compared to angioplasty alone. Clinical trials with a larger sample size will better elucidate the value and timing of angioplasty versus stent placement in cephalic arch stenosis.
- 9 October 2014
- Published by Wiley in Seminars in Dialysis
- Vol. 28 (1) , E7-E10
Open AccessOutcomes of Cephalic Arch Stenosis With and Without Stent Placement after Percutaneous Balloon Angioplasty in Hemodialysis Patients
Cephalic arch stenosis is a common complication in maintenance hemodialysis (MHD) patients with brachial artery‐cephalic vein fistulas and frequently leads to loss of the functioning brachial artery‐cephalic vein fistula. There is paucity of conclusive data to guide appropriate management. We examined the risk of recurrence of cephalic arch stenosis after angioplasty compared to angioplasty after stent placement determined by angiography of the involved upper extremity over time in a contemporary cohort of MHD patients treated in two interventional nephrology practices from March 2008 through May 2011. We retrospectively identified 45 MHD patients with evidence of cephalic arch stenosis (age 60 ± 30 years, 45% men) on elective angiograms. The median number of days until another angioplasty was required decreased, starting with a median of 91.5 days after the first, 70.5 days after the second, 85 days after the third, and 56 days after the fourth. Angioplasty is associated with a faster rate of recurrence of cephalic arch stenosis. The placement of intravascular stent seems to prolong the patency compared to angioplasty alone. Clinical trials with a larger sample size will better elucidate the value and timing of angioplasty versus stent placement in cephalic arch stenosis.
- 1 August 2014
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 60 (2) , 541-542
Migration Towards Proximal Location Improves Maturation Rate of Arteriovenous Fistula
- 1 August 2014
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 60 (2) , 541-542
Migration Towards Proximal Location Improves Maturation Rate of Arteriovenous Fistula
- Open Access
- 9 October 2013
- Published by Wiley in Seminars in Dialysis
- Vol. 27 (4) , 415-423
Association of Vascular Access Type with Inflammatory Marker Levels in Maintenance Hemodialysis Patients
Aggressive NIH is a common histopathological lesion found at the sites of venous stenosis in arteriovenous fistula (AVF) and arteriovenous grafts (AVG). Inflammatory mediators have been proposed to play a pathogenic role in NIH, but there is paucity of data evaluating this hypothesis in clinical studies or in animal models. Serum levels of inflammatory mediators can potentially identify patients at high risk of AVF and AVG dysfunction. In a cross‐sectional cohort study of 754 HD patients who were part of the NIED study cohort, we examined the associations between inflammatory markers including serum interleukin (IL) 1β, IL‐6, C‐reactive protein (CRP), and tumor necrosis factor‐α (TNF‐α) and type of vascular access. Unadjusted and multivariate‐adjusted linear regression models were used. In addition, time‐dependent regression model was used to assess the association between inflammatory markers and mortality. We observed that in the multivariate‐adjusted model, inflammatory mediators interleukin‐6 (IL‐6), interleukin–1L‐ß (IL‐1ß), and C‐reactive protein (CRP), the predicted value in hemodialysis patients, are lowest in patients with AVF and highest in central venous catheter (CVC) and AVG even in case‐mix and malnutrition–inflammation complex syndrome (MICS)‐adjusted models. IL‐6 and CRP levels fall consistently in the same patients when AVG or CVC is changed to AVF and increase if the same patient changes access from AVF to AVG or CVC. Obesity is a risk factor for fistula failure and fistulas are associated with the lowest mortality compared with CVC and AVG. We did not find any statistically significant association between tumor necrosis factor–α (TNF‐ α) and vascular access outcomes. Higher levels of inflammatory mediators seen in CVC and AVG compared with AVF could potentially explain the higher mortality seen in patients with CVC and AVG compared with AVF.
- 9 October 2013
- Published by Wiley in Seminars in Dialysis
- Vol. 27 (4) , 415-423
Open AccessAssociation of Vascular Access Type with Inflammatory Marker Levels in Maintenance Hemodialysis Patients
Aggressive NIH is a common histopathological lesion found at the sites of venous stenosis in arteriovenous fistula (AVF) and arteriovenous grafts (AVG). Inflammatory mediators have been proposed to play a pathogenic role in NIH, but there is paucity of data evaluating this hypothesis in clinical studies or in animal models. Serum levels of inflammatory mediators can potentially identify patients at high risk of AVF and AVG dysfunction. In a cross‐sectional cohort study of 754 HD patients who were part of the NIED study cohort, we examined the associations between inflammatory markers including serum interleukin (IL) 1β, IL‐6, C‐reactive protein (CRP), and tumor necrosis factor‐α (TNF‐α) and type of vascular access. Unadjusted and multivariate‐adjusted linear regression models were used. In addition, time‐dependent regression model was used to assess the association between inflammatory markers and mortality. We observed that in the multivariate‐adjusted model, inflammatory mediators interleukin‐6 (IL‐6), interleukin–1L‐ß (IL‐1ß), and C‐reactive protein (CRP), the predicted value in hemodialysis patients, are lowest in patients with AVF and highest in central venous catheter (CVC) and AVG even in case‐mix and malnutrition–inflammation complex syndrome (MICS)‐adjusted models. IL‐6 and CRP levels fall consistently in the same patients when AVG or CVC is changed to AVF and increase if the same patient changes access from AVF to AVG or CVC. Obesity is a risk factor for fistula failure and fistulas are associated with the lowest mortality compared with CVC and AVG. We did not find any statistically significant association between tumor necrosis factor–α (TNF‐ α) and vascular access outcomes. Higher levels of inflammatory mediators seen in CVC and AVG compared with AVF could potentially explain the higher mortality seen in patients with CVC and AVG compared with AVF.
- 22 August 2012
- Published by Wiley in Seminars in Dialysis
- Vol. 26 (2) , 233-239
Biological Grafts for Hemodialysis Access: Historical Lessons, State‐of‐the‐Art and Future Directions
The vast majority of arteriovenous grafts (AVG) have been constructed using expanded polytetrafluoroethylene (ePTFE). While ePTFE grafts have the advantage of being relatively inexpensive and easy to manufacture, distribute, ship, and store, their primary patency rates are disappointing when compared with the native AVF. Though use of arteriovenous fistulas (AVF) in the United States has increased substantially, approximately 25% of hemodialysis patients continue to use AVG as their vascular access. We present here a comprehensive review of biological grafts and their use in hemodialysis vascular access. In this review, we discuss the use of synthetics and then explore the evolution of biological grafts over the past 20 years, their clinical impact, and future challenges in widespread clinical use in hemodialysis patients. Provided are in depth descriptions of currently used nonbiological arteriovenous grafts and the recent approaches in increasing the patency of synthetic grafts. Recent technological advances using tissue‐engineered AVGs have shown promise for patients receiving hemodialysis and their potential to provide an attractive, viable option for vascular access have been discussed.
- 22 August 2012
- Published by Wiley in Seminars in Dialysis
- Vol. 26 (2) , 233-239
Biological Grafts for Hemodialysis Access: Historical Lessons, State‐of‐the‐Art and Future Directions
The vast majority of arteriovenous grafts (AVG) have been constructed using expanded polytetrafluoroethylene (ePTFE). While ePTFE grafts have the advantage of being relatively inexpensive and easy to manufacture, distribute, ship, and store, their primary patency rates are disappointing when compared with the native AVF. Though use of arteriovenous fistulas (AVF) in the United States has increased substantially, approximately 25% of hemodialysis patients continue to use AVG as their vascular access. We present here a comprehensive review of biological grafts and their use in hemodialysis vascular access. In this review, we discuss the use of synthetics and then explore the evolution of biological grafts over the past 20 years, their clinical impact, and future challenges in widespread clinical use in hemodialysis patients. Provided are in depth descriptions of currently used nonbiological arteriovenous grafts and the recent approaches in increasing the patency of synthetic grafts. Recent technological advances using tissue‐engineered AVGs have shown promise for patients receiving hemodialysis and their potential to provide an attractive, viable option for vascular access have been discussed.
- 1 March 2011
- Published by Wiley in Seminars in Dialysis
- Vol. 24 (2) , 220-230
Outcomes of Brachial Artery–Basilic Vein Fistula
Increasing the creation of arteriovenous fistulas in the maintenance of hemodialysis patients is of great importance to the nephrology community. The creation of the brachial artery-basilic vein fistula is an important option in patients with unsuccessful or failing forearm accesses for hemodialysis. The aim of this study is to review reported outcomes of brachial artery-basilic vein fistulas regarding patency and primary failure rates in comparison with other types of fistulas and grafts in the published literature. We have also described the variations in the surgical technique during creation and the potential influence on outcomes. Based on our review of the literature, the rate of primary failure is approximately 15-20% with a range of 0-40%. The mean 1-year primary patency rate is approximately 72% with a range of 23-90%, and the 2-year primary patency rate is approximately 62% with a range from 11% to 86%. The number of required interventions to maintain patency is lower with brachial artery-basilic vein fistula compared to arteriovenous grafts.
- 1 March 2011
- Published by Wiley in Seminars in Dialysis
- Vol. 24 (2) , 220-230
Outcomes of Brachial Artery–Basilic Vein Fistula
Increasing the creation of arteriovenous fistulas in the maintenance of hemodialysis patients is of great importance to the nephrology community. The creation of the brachial artery-basilic vein fistula is an important option in patients with unsuccessful or failing forearm accesses for hemodialysis. The aim of this study is to review reported outcomes of brachial artery-basilic vein fistulas regarding patency and primary failure rates in comparison with other types of fistulas and grafts in the published literature. We have also described the variations in the surgical technique during creation and the potential influence on outcomes. Based on our review of the literature, the rate of primary failure is approximately 15-20% with a range of 0-40%. The mean 1-year primary patency rate is approximately 72% with a range of 23-90%, and the 2-year primary patency rate is approximately 62% with a range from 11% to 86%. The number of required interventions to maintain patency is lower with brachial artery-basilic vein fistula compared to arteriovenous grafts.